HiberCell
Presença
HiberCell possui 7 subsidiárias incluindo Genuity Science, WuXi Advanced Therapies e WuXi AppTec.
Executivos
Veja o organograma con seus 95 executivos principais
Biografias mais buscadas da HiberCell
- Jonathan Lanfear, President and Chief Executive Officer
- Colin Goddard, Director
- Steven Gillis, Chairman of the Board
Criar um alerta
para seguir os movimentos de executivos da HiberCell.
Biotecnologia
HiberCell possui 2.289 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Delphia Therapeutics acaba de anunciar uma arrecadação de fundos de 67 milhões de dólares. (publicado em 7 de maio de 2024).
- Karius acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 3 de maio de 2024).
- Transcarent acaba de anunciar uma arrecadação de fundos de 126 milhões de dólares. (publicado em 2 de maio de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de HiberCell
- HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC - HiberCell
- HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC) - HiberCell
- HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in Combinations - HiberCell
- HiberCell Doses First Patient in Phase 1b Study Exploring Novel Combination of Odetiglucan and CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) in the Maintenance Setting - HiberCell
- HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023 - HiberCell
- HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023 - HiberCell
- HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML) - HiberCell
- HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - HiberCell
- HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting - HiberCell
- HiberCell and the University of Pennsylvania Present Preclinical Anti-Metastatic Monotherapy Activity Data in Mice for Odetiglucan in Pancreatic Cancer at AACR Annual Meeting 2022 - HiberCell
- View more press releases Close
Redes sociais sobre HiberCell
- HiberCell na Wikipedia, Google News e Yahoo Finance
- HiberCell na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Jonathan Lanfear 
Ligue para a HiberCell em +1 212...
